Program
GFH276
A development code.
Its studies are mostly in Colorectal Neoplasms · Carcinoma, Non-Small-Cell Lung, led by Genfleet Therapeutics (Shanghai).
Furthest: phase 2, since Sep 15, 20253 company-led studies, 3 open or runningNext primary completion: Jul 30, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Genfleet Therapeutics (Shanghai) | 33 open or running | phase 2since Sep 15, 2025 | Sep 15, 2025 | Jul 30, 2027phase 2 · NCT07198321 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 15, 2025First study: phase 2 study in NeoplasmsFirst studyNCT07198321 · 450 planned · China
- Sep 22, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07846358 · 84 planned
- Oct 29, 2026Phase 2 study in CRCNCT07915921 · 150 planned
Ahead
- Jul 30, 2027Primary completion: phase 2 study in NeoplasmsNCT07198321
- Dec 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07846358
- Apr 30, 2028Primary completion: phase 2 study in CRCNCT07915921
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07915921CRC | 2 | Not yet recruiting | Apr 30, 2028 | 150 |
| NCT07846358Carcinoma, Non-Small-Cell Lung | 2 | Not yet recruiting | Dec 2027 | 84 |
| NCT07198321Neoplasms · China | 2 | Recruiting | Jul 30, 2027 | 450 |
How it is read
Names in the registry
- “GFH276”, 3 entries
Codes read as this program: GFH276.
Conditions, from the studies’ own filings
- Colorectal Neoplasms, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.